$10.57
+0.04 (+0.38%)
Open$11.77
Previous Close$10.53
Day High$11.77
Day Low$10.35
52W High$76.00
52W Low$6.34
Volume—
Avg Volume66.0K
Market Cap45.20M
P/E Ratio—
EPS$-3.03
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+88.9% upside
Current
$10.57
$10.57
Target
$19.97
$19.97
$17.96
$19.97 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.10M | 46.49M | 39.49M |
| Net Income | 3.70M | 3.34M | 2.56M |
| Profit Margin | 8.2% | 7.2% | 6.5% |
| EBITDA | 5.80M | 5.78M | 5.15M |
| Free Cash Flow | 3.02M | 2.12M | 2.20M |
| Rev Growth | +4.3% | +20.2% | +6.0% |
| Debt/Equity | 0.88 | 1.05 | 1.14 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |